<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070858</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-MG-2018</org_study_id>
    <secondary_id>2020-003272-41</secondary_id>
    <nct_id>NCT05070858</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis</brief_title>
  <official_title>Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is:&#xD;
&#xD;
      To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by&#xD;
      signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG)&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran&#xD;
           monotherapy on:&#xD;
&#xD;
             -  Clinician-assessed signs of myasthenia gravis (MG) and muscle strength&#xD;
&#xD;
             -  Daily functioning that is impacted by signs and symptoms in patients with&#xD;
                symptomatic gMG (cemdisiran monotherapy only).&#xD;
&#xD;
             -  Proportion of patients with improvements in daily function that is impacted by&#xD;
                signs and symptoms of MG&#xD;
&#xD;
             -  Proportion of patients that have improvements in clinician-assessed signs of MG and&#xD;
                muscle strength&#xD;
&#xD;
             -  Health related quality of life&#xD;
&#xD;
             -  Proportion of patients with minimal MG symptoms&#xD;
&#xD;
             -  Patient- and clinician-reported signs and symptoms of MG&#xD;
&#xD;
        -  To evaluate the safety and tolerability of pozelimab + cemdisiran and cemdisiran&#xD;
           monotherapy&#xD;
&#xD;
        -  To assess the concentration of total pozelimab in serum&#xD;
&#xD;
        -  To assess the concentrations of cemdisiran and its metabolites in plasma&#xD;
&#xD;
        -  To assess the immunogenicity of pozelimab&#xD;
&#xD;
        -  To assess the immunogenicity of cemdisiran&#xD;
&#xD;
        -  To study the effect of pozelimab + cemdisiran and cemdisiran monotherapy on complement&#xD;
           activation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">February 26, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>The total MG-ADL score ranges from 0 to 24 points, with higher scores indicating greater functional impairment and disability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quantitative Myasthenia Gravis (QMG) score</measure>
    <time_frame>Week 24</time_frame>
    <description>QMG total scores range from 0 to 39, with higher scores representing greater impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients responding on the MG-ADL</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>≥3-point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients responding on the QMG</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>≥5-point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with consistent response on the MG-ADL</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>At least a 2-point MG-ADL improvement on 2 or more consecutive assessments spanning 4 or more weeks during the DBTP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with minimal symptom expression (MSE)</measure>
    <time_frame>Week 24</time_frame>
    <description>Score of 0 to 1 on the MG-ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Myasthenia Gravis Composite (MGC) total score</measure>
    <time_frame>Week 24</time_frame>
    <description>MGC score ranges from 0 to 50, with higher score indicating higher impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Myasthenia Gravis Quality of Life (MG QOL15r) total score</measure>
    <time_frame>Week 24</time_frame>
    <description>Total score ranges from 0 to 30 points; a higher score represents greater impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement point thresholds on MG-ADL</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>≥2, 4, 5, 6, 7, 8, 9, or 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement point thresholds on QMG</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>≥3, 4, 6, 7, 8, 9, or 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment-related adverse events (TEAEs) in patients treated with pozelimab + cemdisiran or placebo</measure>
    <time_frame>Through week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs) in patients treated with pozelimab + cemdisiran or placebo</measure>
    <time_frame>Through week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events of special interest (AESIs) in patients treated with pozelimab + cemdisiran or placebo</measure>
    <time_frame>Through week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total pozelimab in serum</measure>
    <time_frame>Through study duration, approximate 172 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of cemdisiran and its metabolites in plasma</measure>
    <time_frame>Through study duration, approximate 172 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibodies (ADAs) to pozelimab over time</measure>
    <time_frame>Through study duration, approximately 172 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent ADAs to cemdisiran over time</measure>
    <time_frame>Through study duration, approximate 172 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CH50 over time</measure>
    <time_frame>Through study duration, approximately 172 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in CH50 over time</measure>
    <time_frame>Through study duration, approximately 172 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Generalized Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP and OLTP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination regimen throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cemdisiran throughout the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pozelimab (REGN3918) + Cemdisiran</intervention_name>
    <description>Subcutaneous administration as described in the protocol</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemdisiran</intervention_name>
    <description>SC administration as described in the protocol</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>ALN-CC5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC administration as described in the protocol</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥18 years of age at screening (or ≥ legal age of adulthood&#xD;
             based on local regulations, whichever is older)&#xD;
&#xD;
          2. Patient with documented diagnosis of myasthenia gravis (MG) based on medical history&#xD;
             and supported by previous evaluations as described in the protocol&#xD;
&#xD;
          3. Documented prior history of positive serologic test or a positive result during&#xD;
             screening of anti-acetylcholine receptor (AChR) antibodies or anti-LRP4 antibodies.&#xD;
&#xD;
          4. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IVa&#xD;
             at screening&#xD;
&#xD;
          5. Myasthenia Gravis-Activities of Daily Living (MG-ADL) score ≥6 at screening. Ocular&#xD;
             items should not contribute more than 50% of MG-ADL total score&#xD;
&#xD;
          6. Currently receiving an acetylcholinesterase inhibitor or documented reason for not&#xD;
             using acetylcholinesterase inhibitor therapy per investigator 7. Currently receiving&#xD;
             an immunosuppressive therapy (IST) for MG, or documented reason why the patient is not&#xD;
             taking an IST per investigator&#xD;
&#xD;
        8. If currently receiving an IST, not anticipated to have IST dosage changed before&#xD;
        randomization or during double-blind treatment period (DBTP).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a positive serologic test for antibodies to muscle specific tyrosine&#xD;
             kinase (MuSK) during screening&#xD;
&#xD;
          2. History of thymectomy within 12 months prior to screening or planned during the study&#xD;
&#xD;
          3. History of malignant thymoma (patients with stage 1 may be enrolled), or history of&#xD;
             cancer within the past 5 years, except for adequately treated basal cell skin cancer,&#xD;
             squamous cell skin cancer, or in situ cervical cancer&#xD;
&#xD;
          4. Myasthenic crisis or Myasthenia Gravis Foundation of America (MGFA) Class V within 1&#xD;
             month of screening&#xD;
&#xD;
          5. No documented meningococcal vaccination within 5 years prior to screening visit unless&#xD;
             vaccination will be administered during the screening period and prior to initiation&#xD;
             of study treatment&#xD;
&#xD;
          6. Known contraindication to meningococcal vaccines (group ACWY conjugate and group B&#xD;
             vaccines) as described in the protocol&#xD;
&#xD;
          7. Patients who require antibiotics for meningococcal prophylaxis and have a&#xD;
             contraindication, warning, or precaution precluding the use of penicillin class and&#xD;
             penicillin-alternative antibiotics planned to be used for prophylaxis, or a history of&#xD;
             intolerance leading to the discontinuation of these antibiotics&#xD;
&#xD;
          8. Positive hepatitis B surface antigen or hepatitis C virus ribonucleic acid (RNA)&#xD;
             during screening. NOTE: Cases with unclear interpretation should be discussed with the&#xD;
             medical monitor&#xD;
&#xD;
          9. History of HIV infection&#xD;
&#xD;
        NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

